Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2003

View Archived Issues

Safety of Sch-55700 in patients with severe persistent asthma

Transient antitumor effects of tipifarnib in hematological malignancies

Good safety and tolerability profile described for entecavir in hepatitis B

Beta-L-Fd4C versus lamivudine and placebo for reducing viral load in patients with HBV infection

Exemestane beneficial in cirrhotic patients with hypogonadism

Treatment failure on ISIS-14803 and HCV resistance

Activated recombinant factor VII may improve bleeding control in cirrhosis

Trichostatin A potentiates the proapoptotic effects of biomodulators on hepatocellular carcinoma

Activation of CB2 receptors induces apoptosis of hepatic myofibroblasts in vitro

Human arginase II: a possible target for the treatment of sexual arousal disorders

Selective MMP-3 inhibitor as a candidate therapeutic for chronic dermal wounds

Stent-induced restenosis reduced by inhibitor of PDGFR-TK

Spotlight on glycyrrhizin, an active component of licorice root

Use of Y5 receptor antagonists in CNS disorders such as depression

HuMax-CD20 effective in depleting B-cells in primate study

Vasogen initiates patient enrollment in pivotal ACCLAIM trial

PT-100 and Rituxan combination trial under way

EMEA approves Pfizer's Genotropin

FDA approves Infanrix fifth dose indication

Immune Response evaluates second-generation HIV vaccine

Ortho-McNeil reveals new erythromycin derivatives

Factor Xa inhibitors and their application described by Lilly

BMS identifies series of HIV integrase inhibitors

Recent Merck patents cover pyrimidinone KSP inhibitors

Second phase of landmark rheumatoid arthritis study program enrolls 5,000 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...